The emerging role of cell surface receptor and protein binding radiopharmaceuticals in cancer diagnostics and therapy
2020 · Nuclear Medicine and Biology · 15 citations
https://doi.org/10.1016/j.nucmedbio.2020.06.005
B
Bala Attili
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
30
Papers
327
Citations
11
h-index
11
i10-index
Bala Attili is an academic researcher from AstraZeneca (United Kingdom). The author has contributed to research in topics: CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers & Medical Imaging Techniques and Applications. The author has an h-index of 11, co-authored 26 publications.
ORCID: 0000-0002-5136-0474Papers by this author
works18th European Symposium on Radiopharmacy and Radiopharmaceuticals
2016 · EJNMMI Radiopharmacy and Chemistry · 6 citations
https://doi.org/10.1186/s41181-016-0012-6
Preclinical evaluation of [18F]cabozantinib as a PET imaging agent in a prostate cancer mouse model
2020 · Nuclear Medicine and Biology · 5 citations
https://doi.org/10.1016/j.nucmedbio.2020.12.002
Data from Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers
2024 · 0 citations
https://doi.org/10.1158/1078-0432.c.7565446
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat